Nomic Closes $17 Million Series A To Develop And Commercialize The World’S Highest Throughput Proteomic Platform

Dec 08, 2021•over 3 years ago

Amount Raised

$17 Million

Round Type

series a

Montreal

Description

Nomic Bio ("Nomic"), the protein profiling company, today announced the closing of an oversubscribed US$17 million Series A funding round, bringing the company's total funding to date to over US$21 million. The round was led by Lux Capital and joined by SR One and Casdin Capital, with participation from prior institutional investors.

Company Information

Company

Nomic

Location

Montreal, Quebec, Canada

About

Nomic (formerly nplex biosciences) is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. We are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. The nELISA was designed to seamlessly integrate into current workflows in biology and is uniquely adaptable to a wide variety of use cases within drug and biomarker development workflows. Nomic is headquartered in Montreal, with labs and offices in Boston. For more information, visit www.nomic.bio.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech